

# SkyePharma

[View the current SkyePharma Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/9587-SkyePharma.html)

(<http://www.bioportfolio.com/bi corporate/9587-SkyePharma.html>)

## Contact Details:

**105 Piccadilly  
London**

Tel: (44) 20 7491 1777

Fax: (44) 20 7491 3338

Email: [ir@skypepharma.com](mailto:ir@skypepharma.com)

**W1J 7NJ**

**United States of America**

SkyePharma uses world-leading drug delivery technology to make good drugs even better. We have the ability to solve over 90% of the industry's formulation and delivery challenges by drawing on the broadest-available range of drug delivery technologies, turning already-proven drugs into more effective and safer medicines. Combining our established pre-clinical, clinical and regulatory expertise with the capability to formulate and manufacture drugs, both for clinical studies and commercial sale, we identify and develop new therapeutics for ourselves and for our partners.

## Recent Publications by SkyePharma:



- [Measurement of protein diffusion through poly\(D,L-lactide-Co-glycolide\).](#)  
*A novel method was developed for studying the diffusion of proteins...*3rd August, 2005  
SkyePharma AB, Malmo, Sweden.- Pharm Dev Technol. 2005;10(2):299-307.
- [A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.](#)  
*BACKGROUND: The main drawback of the lipid-lowering agent fenofibrate is...*26th January, 2005  
SkyePharma- Clin Ther. 2004 Sep;26(9):1456-69. ([DOI Direct Link](#))
- [Modulation of the sustained delivery of myelopoietin \(Leridistim\) encapsulated in multivesicular liposomes \(DepoFoam\).](#)  
*Myelopoietins (MPO) are novel chimeric growth factors containing IL-3 and...*13th January, 2004  
SkyePharma Inc., 10450 Science Center Drive, San Diego, CA 92121, USA.- J Control Release. 2003 Apr 14;89(1):87-99.
- [The sustained granulopoietic effect of progenipoietin encapsulated in multivesicular liposomes.](#)  
*Progenipoietin (ProGP), a dual receptor agonist of fetal liver tyrosine...*10th October, 2003  
SkyePharma Inc., 10450 Science Center Drive, 92121, San Diego, CA, USA.- Int J Pharm. 2003 Aug

11;261(1-2):93-103.

- [Determination of fat content and fatty acid composition in meat and meat products after supercritical fluid extraction.](#)

*Two different relatively simple, commercially available supercritical...* 2nd April, 2003  
Swedish- J AOAC Int. 2002 Sep-Oct;85(5):1064-9.

- [Power of experimental design studies for the validation of pharmaceutical processes: case study of a multilayer tablet manufacturing process.](#)

*Experimental design studies (EDS) are already widely used in the...* 13th March, 2003  
Process Development and Engineering Department, SkyePharma AG, 51- Drug Dev Ind Pharm. 2002 Aug;28(7):841-8.

- [A lipid based depot \(DepoFoam technology\) for sustained release drug delivery.](#)

*Encapsulation of drugs into multivesicular liposomes (DepoFoam) offers a...* 26th November, 2002  
SkyePharma Inc., 10450 Science Center Drive, San Diego, CA 92121, USA.- Prog Lipid Res. 2002 Sep;41(5):392-406.

## BioNews Results for SkyePharma



- [Nitec Pharma Gets \\$22M to Fund Lodotra Launch](#)

*BioWorld: Oct 4 2008 9:49PM Matching: skyepharma*

- [Skyepharma PLC: Skyepharma - Statement re Convertible Bonds](#)

*Market Wire: Oct 3 2008 10:18AM Matching: skyepharma*

- [Skyepharma - Statement re Convertible Bonds](#)

*Macro World Investor: Oct 3 2008 10:24AM Matching: skyepharma*

- [Skyepharma - Statement re Convertible Bonds](#)

*Market Wire: Oct 3 2008 10:23AM Matching: skyepharma*

- [Skyepharma - Statement re Convertible Bonds](#)

*Street Insider: Oct 3 2008 10:22AM Matching: skyepharma*

- [Skyepharma - Statement re Convertible Bonds](#)

*Stockwatch: Oct 3 2008 10:19AM Matching: skyepharma*

- [Skyepharma - Statement re Convertible Bonds](#)

*MarketWatch: Oct 3 2008 10:33AM Matching: skyepharma*

- [Skyepharma - Statement re Convertible Bonds](#)

*Houston Chronicle: Oct 3 2008 10:31AM Matching: skyepharma*

- [Skyepharma - Statement re Convertible Bonds](#)

*Earthtimes.org: Oct 3 2008 10:26AM Matching: skyepharma*

- [Skyepharma - Statement re Convertible Bonds](#)

*Yahoo! Canada: Oct 3 2008 10:17AM Matching: skyepharma*

- [SkyePharma Implements Revised Terms for Convertible Bonds - Quick Facts](#)

*RTTNews.com: Oct 3 2008 10:57AM Matching: skyepharma*

- [Skyepharma - Statement re Convertible Bonds](#)

*Calibre Macro World: Oct 3 2008 10:10AM Matching: skyepharma*

- [SkyePharma PLC - American Depositary Shares reverse split today 1:10](#)

*Calibre Macro World: Oct 2 2008 6:36PM Matching: skyepharma*

- [SkyePharma PLC - American Depositary Shares reverse split today 1:10](#)

*Macro World Investor: Oct 2 2008 5:39PM Matching: skyepharma*

- [High Growth Reported for the World Pulmonary Drug Delivery Technologies Market](#)

*Houston Chronicle: Oct 2 2008 1:25AM Matching: skyepharma*





## SkyePharma Patents:

- 7131441- [Inhaler for multiple dosed administration of a pharmacological dry powder](#)
- 5997899- [Method for producing liposomes with increased percent of compound encapsulated](#)
- 6045824- [Sustained-release liposomal anesthetic compositions](#)
- 6071534- [Multivesicular liposomes with controlled release of active agents encapsulated in the presence of a hydrochloride](#)
- 6106858- [Modulation of drug loading in multivesicular liposomes](#)
- 6132766- [Multivesicular liposomes with controlled release of encapsulated biologically active substances](#)
- 6159955- [Use of hyaluronic acid and a NSAID for the manufacture of a medicament for the treatment of mucosal diseases](#)
- 6171613- [Method for producing liposomes with increased percent of compound encapsulated](#)
- 6193998- [Method for producing liposomes with increased percent of compound encapsulated](#)
- 6241999- [Method for producing liposomes with increased percent of compound encapsulated](#)
- 6277413- [Biodegradable compositions for the controlled release of encapsulated substances](#)
- 6306432- [High and low load formulations of IGF-I in multivesicular liposomes](#)
- 6428529- [Epidural administration of therapeutic compounds with sustained rate of release](#)
- 6534088- [Fibrate-statin combinations with reduced fed-fasted effects](#)
- 6576264- [Insoluble drug delivery](#)
- 6604698- [Media milling](#)
- 5993850- [Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months

old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

